295 related articles for article (PubMed ID: 19014887)
1. Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both.
Ozer F; Tiras R; Cetin S; Ozturk O; Aydemir T; Ozben S; Meral H; Kizkin S; Bader H; Ozben B
J Clin Neurosci; 2009 Jan; 16(1):83-7. PubMed ID: 19014887
[TBL] [Abstract][Full Text] [Related]
2. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
Kim JY; Chung EJ; Park SW; Lee WY
Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
[TBL] [Abstract][Full Text] [Related]
3. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
Junghanns S; Fuhrmann JT; Simonis G; Oelwein C; Koch R; Strasser RH; Reichmann H; Storch A
Mov Disord; 2007 Jan; 22(2):234-8. PubMed ID: 17094087
[TBL] [Abstract][Full Text] [Related]
4. Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide.
Chung EJ; Yoon WT; Kim JY; Lee WY
Mov Disord; 2006 Apr; 21(4):586-7. PubMed ID: 16482572
[No Abstract] [Full Text] [Related]
5. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
Dewey RB; Reimold SC; O'Suilleabhain PE
Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
[TBL] [Abstract][Full Text] [Related]
6. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
[TBL] [Abstract][Full Text] [Related]
7. [Pergolide: a useful agonist for the treatment of Parkinson disease].
Bonnet AM; Houeto JL
Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
[TBL] [Abstract][Full Text] [Related]
8. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
[TBL] [Abstract][Full Text] [Related]
9. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
[TBL] [Abstract][Full Text] [Related]
10. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
[TBL] [Abstract][Full Text] [Related]
11. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
Yamamoto M; Uesugi T; Nakayama T
Neurology; 2006 Oct; 67(7):1225-9. PubMed ID: 17030757
[TBL] [Abstract][Full Text] [Related]
12. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients.
Kulisevsky J; López-Villegas D; García-Sánchez C; Barbanoj M; Gironell A; Pascual-Sedano B
Clin Neuropharmacol; 1998; 21(6):358-62. PubMed ID: 9844794
[TBL] [Abstract][Full Text] [Related]
13. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
Pezzoli G; Martignoni E; Pacchetti C; Angeleri VA; Lamberti P; Muratorio A; Bonuccelli U; De Mari M; Foschi N; Cossutta E
Mov Disord; 1994 Jul; 9(4):431-6. PubMed ID: 7969210
[TBL] [Abstract][Full Text] [Related]
14. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
15. Trial of subtherapeutic pergolide in de novo Parkinson's disease.
Grosset K; Grosset D; Lees A;
Mov Disord; 2005 Mar; 20(3):363-6. PubMed ID: 15580607
[TBL] [Abstract][Full Text] [Related]
16. Pergolide and Parkinson's disease: new preparation. No clear benefit.
Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
[TBL] [Abstract][Full Text] [Related]
17. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
[TBL] [Abstract][Full Text] [Related]
18. Valvular heart disease in patients taking pergolide.
Waller EA; Kaplan J; Heckman MG
Mayo Clin Proc; 2005 Aug; 80(8):1016-20. PubMed ID: 16092580
[TBL] [Abstract][Full Text] [Related]
19. Bromocriptine use and the risk of valvular heart disease.
Tan LC; Ng KK; Au WL; Lee RK; Chan YH; Tan NC
Mov Disord; 2009 Feb; 24(3):344-9. PubMed ID: 18989898
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
